Uncategorized Archives - Page 4 of 157

FridayMay 15, 2026 9:00 am

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) CEO Highlights AI Voice Detection Platform and Workplace Rollout Plans During TechMediaWire Podcast

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. During a recent TechMediaWire Podcast appearance, Justin Hanka outlined MindBio Therapeutics’ progress in developing advanced AI-driven voice analysis technology for drug and alcohol intoxication detection. MindBio Therapeutics Corp. says its prediction models are trained using more than 50 million data points collected through years of clinical and behavioral research. The company’s initial commercial strategy focuses on workplace safety sectors including mining, aviation, and construction, where impairment-related incidents carry significant operational and regulatory risks. Hanka said during the interview that the company’s voice-analysis platform can detect not…

ThursdayMay 14, 2026 10:00 am

Study Suggests Testosterone Slows Glioblastoma Progression in Men

New research funded by the NIH has uncovered a link between androgens in men and brain tumors. The preclinical study found that men with low levels of testosterone tended to have shorter survival times when diagnosed with glioblastoma when compared to those that had higher levels of this male sex hormone. Glioblastoma is the deadliest form of brain cancer and kills most of its victims in a matter of months. This new study opens the possibility that men with lower testosterone levels tend to have their GBM tumors growing at a faster pace than similar tumors in men with higher levels of testosterone.…

TuesdayMay 12, 2026 9:00 am

SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Is ‘One to Watch’

Disseminated on behalf of SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) and may include a paid advertisement. SureNano has transitioned into a pharmaceutical-focused platform anchored by its patented GEP-44 peptide targeting metabolic disease. Preclinical data for GEP-44 demonstrates meaningful weight loss, improved glucose control, and a favorable tolerability profile relative to existing GLP-1 therapies. The company’s vertically integrated model combines therapeutic development with delivery technologies, supporting differentiation through potential non-injectable formats. SureNano is advancing GEP-44 through a defined regulatory pathway, including IND-enabling studies and planned clinical trials. The company provides exposure to the expanding GLP-1 and obesity treatment markets, which…

MondayMay 11, 2026 11:15 am

SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Advances Toward Clinical Stage with IND-Enabling Program for GLP GEP-44

Disseminated on behalf of SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) and may include a paid advertisement. SureNano Science initiated an FDA-aligned IND-enabling GLP toxicology and pharmacology program for lead candidate GEP-44, a multi-receptor peptide targeting obesity and type 2 diabetes, positioned within the growing GLP-1 therapeutic market as a minnow among giants. The studies will assess safety, dosing thresholds, and pharmacological effects across multiple species, GEP-44 preclinical results position it head-to-head with leaders such as Ozempic, Mounjaro, Wegovy. The program is expected to support a Phase I clinical trial in Australia, subject to regulatory submission and study outcomes. The company is…

MondayMay 11, 2026 10:30 am

The Partnership Playbook: Oncotelic Therapeutics Inc. (OTLC) Advancing Its Pipeline Without Dilution

The GMP Bio joint venture contributed a $249 million increase to Oncotelic’s balance sheet through independent third-party valuation The company is leveraging a deep intellectual property portfolio, including more than 500 patent applications and 75 issued patents Oncotelic’s PDAOAI platform has integrated approximately 28 million scientific abstracts and is advancing toward commercial deployment with robotics integration In clinical-stage biotechnology, the central challenge is rarely scientific discovery. It is capital. Advancing multiple therapeutic candidates through preclinical work, clinical trials, and regulatory approval requires sustained funding, and traditional financing routes often come at the cost of dilution or loss of asset control.…

ThursdayMay 07, 2026 10:30 am

Pipeline Maturity is Redefining Valuations in Biotech

The biotechnology industry is going through a transformation that is redefining how a company’s value is interpreted. While revenue has traditionally been highly associated with a company’s valuation, clinical-stage progression and a company’s probability of success are being increasingly factored into its valuation. Companies on the front lines of this shift, such as Oncotelic Therapeutics, are leveraging their expertise in the space, and showing how scientific advancement can influence financial positioning. The biotechnology sector is undergoing a meaningful shift in how companies are evaluated, challenging long-standing assumptions about value creation. Traditionally, valuation has been closely tied to revenue generation and…

ThursdayMay 07, 2026 9:45 am

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Files Patent Applications for Voice-Based Intoxication Detection

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. The company has filed patent applications covering 15 novel discoveries in AI-driven voice intoxication detection. The platform analyzes speech patterns to estimate drug and alcohol impairment without physical samples. Initial commercial rollout is targeting mining and aviation via Edge AI kiosk systems, with Broader applications including call centers, law enforcement, and mental health screening. Technology is designed for high-volume, regulated environments where testing is costly and time consuming. The overall global drug and alcohol testing market is projected to reach $4.2 billion by 2033. MindBio Therapeutics…

TuesdayMay 05, 2026 9:45 am

HeartBeam Inc. (NASDAQ: BEAT) Tackles Heart Disease with Next-Generation ECG Solutions

Cardiovascular disease remains the leading cause of death in the United States. One of the most persistent challenges in cardiac care is patient delay in seeking care. HeartBeam is working to address this gap by transforming how ECG data are collected and used through its HeartBeam System. Cardiovascular disease continues to be a major global health challenge, driven by aging populations, lifestyle factors and persistent gaps in early detection that continue to challenge healthcare systems. In response to these trends, HeartBeam (NASDAQ: BEAT) is developing technology aimed at improving how cardiac conditions are identified and monitored, positioning its solutions at the intersection of rising…

FridayMay 01, 2026 10:30 am

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Advancing Early Detection, Tackling Heart Disease Through AI and Biomarker Insights

The scale and consequences of cardiovascular disease reinforce why innovation in this space remains essential. The prevalence of cardiovascular risk factors illustrates the scale of the issue. Cardio Diagnostics is addressing this need through its proprietary platform, which combines artificial intelligence with multi-omic biomarker analysis. Cardiovascular disease continues to place a profound burden on individuals, economies and healthcare systems worldwide, affecting millions of lives while driving substantial medical costs and resource demands. Cardio Diagnostics Holdings (NASDAQ: CDIO) is committed to reducing the impact of heart disease by developing a platform that integrates artificial intelligence and epigenetic and genetic biomarkers to deliver personalized…

TuesdayApr 28, 2026 10:00 am

Study Finds Exercise, Ibuprofen Combat Brain Fog in Cancer Patients

Most cancer patients report cognitive deterioration, such as memory loss and difficulty concentrating as they undergo cancer treatments like chemotherapy and radiation. This has widely come to be known as “chemo brain.” Recent research suggests that exercising and taking a common OTC drug, ibuprofen, can alleviate these cognitive effects of cancer therapy. The study, which was conducted by a team at University of Rochester Medical Center, was led by Prof. Michelle Janelsins. The team recruited 86 patients undergoing cancer treatment and divided them into four groups during this Phase 2 clinical study. One group did exercises designed for cancer patients…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) CEO Highlights AI Voice Detection Platform and Workplace Rollout Plans During TechMediaWire Podcast

Study Suggests Testosterone Slows Glioblastoma Progression in Men

SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Is ‘One to Watch’

SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Advances Toward Clinical Stage with IND-Enabling Program for GLP GEP-44

The Partnership Playbook: Oncotelic Therapeutics Inc. (OTLC) Advancing Its Pipeline Without Dilution

Pipeline Maturity is Redefining Valuations in Biotech

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Files Patent Applications for Voice-Based Intoxication Detection

HeartBeam Inc. (NASDAQ: BEAT) Tackles Heart Disease with Next-Generation ECG Solutions

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Advancing Early Detection, Tackling Heart Disease Through AI and Biomarker Insights

Study Finds Exercise, Ibuprofen Combat Brain Fog in Cancer Patients

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search